# data[].attributes.attachment_link.readable_text
The data from the abstracts demonstrate the use of Viz's AI platform in improving workflows and disease detection. Image Credit: Golden Dayz / Shutterstock.

US-based Viz.ai has released new trial data that assessed its artificial intelligence (AI) powered neurovascular technology to detect and diagnose neurology pathologies including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA) and brain haemorrhage.

The Viz aneurysm algorithm was evaluated in a retrospective trial that examined head computed tomography (CT) scans. Across 963 scans, the algorithm showed a specificity of 96.8% and a negative predictive value of 97.2%. The software can be used to improve workflow and triage patients.

The user engagement with Viz.ai's large vessel occlusions (LVO) detection software was evaluated in a multicentre, prospective, randomised clinical trial. The study found that there was an 11-minute reduction in door-to-groin puncture (DTG) time across all centres with Viz LVO implementation. DGT signifies the time required for a patient to reach the neuro-interventional radiology (IR) suite for mechanical thrombectomy, with a shorter time being associated with better clinical outcomes.

Another single-centre trial evaluated the impact of the software by measuring door-to-angiography time pre- and post-implementation of LVO software. The study showed that LVO software implementation was associated with shorter intervals between initial hospital contact and neurointerventional among transferred patients. The cleared by the FDA LVO software and is distributed in the US by Medtronic.

The evaluation of Viz.ai's convolutional neural network (CNN), Viz ICH+, showed that the system can automatically quantify intracranial haemorrhage (ICH) and lateral ventricular (LV) volumes as well as midline shift (MLS) compared to the more time intensive, manual neuroradiologists segmentation. Viz.ai's acute ischaemic stroke triage software showed a reduction in time-to-treatment and a reduction in unnecessary transfers during a two-year period when implemented in a large academic healthcare system.

The data from the abstracts demonstrate the use of Viz's AI platform in improving workflows and disease detection. GlobalData forecasts AI to be a key driver of medical device innovation. The AI market generated approximately $93bn in sales in 2023, as per GlobalData analysis. Multiple companies, such as Roche and Amazon, have developed AI algorithms to improve workflows and disease diagnosis.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile - free sample

# data[].attributes.attachment_link.title
Viz.ai's aneurysm diagnostic tool is 97.2% predictive in ruling out stroke

# data[].attributes.attachment_link.description
The AI-powered diagnostic platform can diagnose the presence of aneurysms by analysing computed tomography (CT) scans.

# data[].attributes.body
AI is a state-of-the-art resource that has been implemented in several areas of our life. Your phone's face ID login, bank account alerts, social media suggestions, etc. The current invocation is to bring this technology into the medical felid. Viz.AI is improving the accuracy of diagnosis of " LVO" or Ischemic Strokes. AI has many indications and implications in the future of medicine.

# data[].attributes.body
1. Pros of this is improving the accuracy of Large Vessel Occlusion diagnosis.

2. Improves Life-altering door-to-puncture time improved by an average of 11 minutes.

3. AI has increased the time to read for Imaging.

4. AI has access to hundreds of database and images to compare.

# data[].attributes.body
1. A simple internet connection loss due to many uncontrollable factors makes this service unable.

2. Reduction of good quality physical assessment and clinical gestalt.

3. AI, just like any other Technolgy, can be hijacked and altered for nefarious purposes.

# data[].attributes.body
My opinion on this up-and-coming use of AI comes with some reluctance. Having a " second" opinion in diagnosing a time-sensitive disease like CVA is unreplaceable but has some trade-offs. More and More providers may rely on AI radiology interpretation, and AI doesn't have access to the whole picture. Access to the patient. In nursing school, we were taught not to treat the monitor, treat the patient. Slowly and slowly, we are becoming less reliant on our face-to-face examinations and more on lab values, CT reads, and vital signs to perform the next intervention.

# data[].attributes.body
1. Maximizer

2. Deliberative

3. Adaptability

4. Ideation

5. Significance

# data[].attributes.body
1.Faith and her Futuristic strength would be helpful in think about the resourcefulness of AI and the future.

2.Carter is a great communicator. This will help minimize any items that may " fall through the cracks".

3.Pablo will have a positive input on the benefits of AI and summarized the " good" outcomes with AI.

4.Shelia is very strategic and able to plan out each step very thoroughly.

5.William has the strength of Woo. Having this skill will help be able to present this project will some extra " pizzazz"

# data[].attributes.body
Deswal, P. (2024, February 8). Viz.ai’s aneurysm diagnostic tool is 97.2% predictive in ruling out stroke. Medical Device Network. https://www.medicaldevice-network.com/news/viz-ais-aneurysm-diagnostic-tool-is-97-2-predictive-in-ruling-out-stroke/?cf-view

Yahav-Dovrat, A., Saban, M., Merhav, G., Lankri, I., Abergel, E., Eran, A., Tanne, D., Nogueira, R. G., & Sivan-Hoffmann, R. (2021). Evaluation of Artificial Intelligence-Powered Identification of Large-Vessel Occlusions in a Comprehensive Stroke Center. AJNR. American journal of neuroradiology, 42(2), 247–254. https://doi.org/10.3174/ajnr.A6923